Prothena Corporation plc Logo

Email this page: News Release

Prothena Receives FDA Fast Track Designation for NEOD001, a Monoclonal Antibody for the Treatment of Patients With AL Amyloidosis

For security reasons, registration is required before you can use this feature.
* Indicates required field